IP Library › Granted Patent US 10,239,929
Granted Patent B2
US 10,239,929 · App. 15/830,123 · Granted Mar 26, 2019

Peptide analogs for treating diseases and disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,239,929
App. No.
15/830,123
Granted
Mar 26, 2019
Kind
B2
Abstract

Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 17 are administered.

Claims (19)

1. A method for treating osteoporosis, or osteoarthritis in a patient in need of such treatment, comprising administering to the patient an effective amount of a peptide selected from the group consisting of:

AcCSNLSTCVLGRLSQELHRLQTFPRTDVGA

SEQ ID NO: 12

NTAcY

AcCSNLSTCVLGKLSQELHKLQTYPRTDVGA

SEQ ID NO: 15

NAP-NH 2

SuccCSNLSTCVLGKLSQELHKLQTYPRTDV

SEQ ID NO: 17

GANAY-NH 2 .

2. The method of claim 1 , wherein the peptide is:

AcCSNLSTCVLGKLSQELHKLQTYPRTDVGA

SEQ ID NO: 15

NAP-NH 2 .

3. The method of claim 1 , wherein the peptide is formulated in a pharmaceutical composition for enteral administration.

4. The method of claim 1 , wherein the peptide is formulated in a pharmaceutical composition for parenteral administration.

5. The method of claim 1 , wherein the peptide is formulated in a pharmaceutical composition comprising a carrier for oral administration.

6. The method of claim 5 , wherein the carrier comprises N-(5-chlorosalicyloyI) -8-aminocaprylic acid (5-CNAC), sodium salt of 10-(2-Hydroxybenzamido) decanoic acid (SNAD), or sodium salt of N-(8[2-hydroxybenzoyl]amino)caprylic acid (SNAC).

7. The method of claim 1 , wherein the peptide is formulated in a pharmaceutical composition for oral administration comprising coated citric acid particles, and wherein the coated citric acid particles increases the oral bioavailability of the peptide.